Bendamustine Formulation for Small-Volume Stable IV Infusion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bendamustine formulations have solubility limitations at 2-8°C, requiring large infusion volumes and long administration times, which can cause side effects like extravasation and patient discomfort, and necessitate immediate preparation and administration due to chemical instability.
Innovation Solution
A liquid composition containing bendamustine hydrochloride, polyethylene glycol, propylene glycol, and an antioxidant in a parenterally acceptable diluent is administered over a short period (≤30 minutes) using smaller volumes (50-325 ml) to maintain solubility and avoid precipitation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If bendamustine is administered using conventional formulations (Bendeka®, Genoptix), then the drug can be delivered, but the administration time is prolonged (at least 30 minutes) and the formulation requires large volume (250 mL or more)
Solution Approach 1:
The patent changes the concentration parameter of bendamustine from conventional low concentrations (0.2-2 mg/mL) to high concentration (10-50 mg/mL). This parameter change enables the same drug dose to be delivered in much smaller volume (e.g., 50 mg dose in 1-5 mL vs. 250+ mL), directly resolving the contradiction between administration time and formulation volume.
Solution Approach 2:
The patent transitions from conventional large-volume slow infusion to small-volume rapid bolus injection. This dimensional change in administration approach allows the drug to be delivered quickly without requiring large volumes, overcoming the limitation of conventional formulations.
2Quantity of substance
If bendamustine concentration is increased to reduce formulation volume, then smaller administration volume is achieved, but the drug tends to precipitate out of solution
Solution Approach 1:
The patent uses specific excipients (surfactants like polysorbate 80, hydrophilic polymers like polyethylene glycol) as intermediaries to stabilize bendamustine at high concentrations. These additives prevent precipitation by maintaining drug solubility, enabling the formulation to achieve both high concentration and stability simultaneously.
Solution Approach 2:
The patent creates a composite formulation system combining bendamustine with multiple stabilizing excipients (surfactants, polymers, buffers). This composite approach allows the formulation to maintain high drug concentration while preventing precipitation through the synergistic effects of multiple stabilizing components.
3Productivity
If bendamustine is formulated at high concentration for small volume administration, then administration time can be reduced, but formulation complexity increases due to need for stabilizing additives
Solution Approach 1:
The patent incorporates stabilizing excipients and buffering agents in advance during formulation preparation. This preliminary action ensures the formulation remains stable at high concentrations without requiring complex storage conditions or additional stabilization steps during administration, thereby maintaining administrative efficiency while managing formulation complexity.
Data Source
AI summary
Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.